Nothing Special   »   [go: up one dir, main page]

ATE247654T1 - Neue heterozyklische verbindungen - Google Patents

Neue heterozyklische verbindungen

Info

Publication number
ATE247654T1
ATE247654T1 AT98955935T AT98955935T ATE247654T1 AT E247654 T1 ATE247654 T1 AT E247654T1 AT 98955935 T AT98955935 T AT 98955935T AT 98955935 T AT98955935 T AT 98955935T AT E247654 T1 ATE247654 T1 AT E247654T1
Authority
AT
Austria
Prior art keywords
substituted
group
atom
heterocyclic
pharmaceutically acceptable
Prior art date
Application number
AT98955935T
Other languages
English (en)
Inventor
Ayumu Kurimoto
Tetsuhiro Ogino
Hajime Kawakami
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE247654T1 publication Critical patent/ATE247654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
AT98955935T 1997-11-28 1998-11-26 Neue heterozyklische verbindungen ATE247654T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34742297 1997-11-28
JP36745197 1997-12-11
JP36744997 1997-12-17
PCT/JP1998/005318 WO1999028321A1 (fr) 1997-11-28 1998-11-26 Nouveaux composes heterocycliques

Publications (1)

Publication Number Publication Date
ATE247654T1 true ATE247654T1 (de) 2003-09-15

Family

ID=27341247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98955935T ATE247654T1 (de) 1997-11-28 1998-11-26 Neue heterozyklische verbindungen

Country Status (12)

Country Link
US (1) US6329381B1 (de)
EP (1) EP1035123B1 (de)
JP (1) JP4375901B2 (de)
KR (1) KR100613634B1 (de)
AT (1) ATE247654T1 (de)
AU (1) AU732361B2 (de)
CA (1) CA2311742C (de)
DE (1) DE69817393T2 (de)
ES (1) ES2205573T3 (de)
NZ (1) NZ504800A (de)
TW (1) TWI222973B (de)
WO (1) WO1999028321A1 (de)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2006091720A2 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
DE60228229D1 (de) * 2001-04-17 2008-09-25 Dainippon Sumitomo Pharma Co Neue adeninderivate
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
US20030133913A1 (en) * 2001-08-30 2003-07-17 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1719511B1 (de) * 2001-11-16 2008-12-10 3M Innovative Properties Company N-[4-(4-Amino-2-ethyl-1H-imidazo[4,5-c]chinolin-1-yl)butyl]methanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US7189730B2 (en) 2001-12-18 2007-03-13 Cv Therapeutics, Inc. A2A adenosine receptor antagonists
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
JP2005518433A (ja) 2002-02-22 2005-06-23 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖｂ−誘導免疫抑制を軽減し治療する方法
GB0215293D0 (en) * 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
ATE488246T1 (de) 2002-08-15 2010-12-15 3M Innovative Properties Co Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
WO2004029054A1 (ja) * 2002-09-27 2004-04-08 Sumitomo Pharmaceuticals Company, Limited 新規アデニン化合物及びその用途
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004053057A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
EP1578419A4 (de) 2002-12-30 2008-11-12 3M Innovative Properties Co Immunstimulierende kombinationen
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
JP2006519020A (ja) * 2003-02-27 2006-08-24 スリーエム イノベイティブ プロパティズ カンパニー Ｔｌｒ介在生物活性の選択的調節
WO2004078138A2 (en) 2003-03-04 2004-09-16 3M Innovative Properties Company Prophylactic treatment of uv-induced epidermal neoplasia
MXPA05009694A (es) * 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
EP1603476A4 (de) 2003-03-13 2010-01-13 3M Innovative Properties Co Verfahren zur entfernung von tätowierungen
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
JP2007500210A (ja) * 2003-04-10 2007-01-11 スリーエム イノベイティブ プロパティズ カンパニー 金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達
KR20060054371A (ko) * 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
CN1852711A (zh) * 2003-08-05 2006-10-25 3M创新有限公司 使用免疫响应调节化合物的传染病预防
CA2535117A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
CA2536136C (en) 2003-08-27 2012-10-30 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004268665A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
AU2004271972B2 (en) 2003-09-05 2010-06-03 Anadys Pharmaceuticals, Inc. TLR7 ligands for the treatment of hepatitis C
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2543685A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
WO2005048933A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
CN1906192A (zh) 2003-11-14 2007-01-31 3M创新有限公司 羟胺取代的咪唑环化合物
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005063744A2 (en) * 2003-12-22 2005-07-14 K.U. Leuven Research & Development IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
EP1699788A2 (de) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005092892A1 (ja) * 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. ８−オキソアデニン化合物
AU2005226359B2 (en) 2004-03-26 2011-02-03 Astrazeneca Aktiebolag 9-substituted 8-oxoadenine compound
EP1740587A4 (de) * 2004-04-02 2009-07-15 Adenosine Therapeutics Llc Selektive antagonisten von a2a-adenosinrezeptoren
US20070166384A1 (en) * 2004-04-09 2007-07-19 Zarraga Isidro Angelo E Methods , composition and preparations for delivery of immune response modifiers
ES2560449T3 (es) 2004-05-28 2016-02-19 Oryxe Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006023381A1 (en) * 2004-08-16 2006-03-02 Taigen Biotechnology Pyrimidinone compounds
WO2006029223A2 (en) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Method for stimulating the immune response of newborns
EP2561872B1 (de) 2004-12-17 2014-09-10 Anadys Pharmaceuticals, Inc. 3, 5-DISUBSTITUTIERTE UND 3,5,7-TRISUBSTITUIERTE 3H-OXAZOLO [4,5-d]PYRIMIDIN-2-ON VERBINDUNGEN UND PRODRUGS
SI1841765T1 (sl) * 2004-12-21 2009-08-31 Gilead Sciences Inc Imidazo(4,5-c)piridinska spojina in postopek za antivirusno zdravljenje
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
WO2006071997A2 (en) 2004-12-30 2006-07-06 3M Innovative Properties Company Treatment for cutaneous metastases
EP1831221B1 (de) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituierte, chirale, fusionierte 1,2 imidazo-4,5-c-ringverbindungen
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
JP2009504803A (ja) * 2005-08-22 2009-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒアゴニスト
TW200801003A (en) * 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034916A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939202A4 (de) * 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co Neue adeninverbindung
US20090192153A1 (en) * 2005-09-22 2009-07-30 Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan Novel adenine compound
TW200745114A (en) * 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
JPWO2007034882A1 (ja) * 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
AU2006318260B2 (en) 2005-11-21 2012-05-17 Anadys Pharmaceuticals, Inc. Process for the preparation of 5-amino-3H- thiazolo [4 , 5 -d] pyrimidin- 2 -one
WO2007060918A1 (ja) 2005-11-24 2007-05-31 Dainippon Sumitomo Pharma Co., Ltd. 新規なメモリーｃｔｌ誘導増強剤
EP3085373A1 (de) 2006-02-22 2016-10-26 3M Innovative Properties Company Konjugate zur modifizierung von immunreaktionen
AU2007257423B8 (en) * 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
EP2034834B1 (de) 2006-06-22 2011-01-26 Anadys Pharmaceuticals, Inc. Prodrugs von 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazol[4,5-d]pyrimidin-2,7-dion
US8138172B2 (en) * 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
CA2656415C (en) * 2006-07-07 2012-05-22 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
EP2040712B1 (de) 2006-07-18 2011-03-02 Anadys Pharmaceuticals, Inc. Carbonat- und carbamat-prodrugs von thiazolo [4,5-d]-pyrimidinen
TW200831105A (en) * 2006-12-14 2008-08-01 Astrazeneca Ab Novel compounds
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
AU2008227128B2 (en) 2007-02-07 2012-12-06 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
DK2132209T3 (da) 2007-03-19 2014-04-14 Astrazeneca Ab 9-substituerede 8-oxo-adeninforbindelser som modulatorer af tlr7 (toll-like receptor 7)
ES2373616T3 (es) * 2007-03-19 2012-02-07 Astrazeneca Ab Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7).
TW200902018A (en) * 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
JPWO2008114819A1 (ja) * 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
CN101687867B (zh) 2007-05-08 2013-10-02 阿斯利康(瑞典)有限公司 具有免疫调节性质的咪唑并喹啉
EP2170888B1 (de) * 2007-06-29 2015-04-22 Gilead Sciences, Inc. Purinderivate und ihre verwendung als modulatoren des toll-like-rezeptors 7
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009034386A1 (en) * 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PE20091156A1 (es) 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
WO2009091031A1 (ja) * 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co., Ltd. アデニン化合物の製造方法
JP5577099B2 (ja) 2008-01-17 2014-08-20 大日本住友製薬株式会社 アデニン化合物の製造方法
AU2009210655B2 (en) * 2008-02-07 2013-08-15 Telormedix Sa Treatment of bladder diseases with a TLR7 activator
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2607365A1 (de) 2009-02-11 2013-06-26 The Regents of The University of California Modulatoren des toll-ähnlichen Rezeptors und Behandlung von Krankheiten
WO2010126101A1 (ja) 2009-04-28 2010-11-04 全薬工業株式会社 プリン誘導体およびそれを用いた抗腫瘍剤
EP2432768B1 (de) 2009-05-21 2017-07-05 Sumitomo Dainippon Pharma Co., Ltd. Neue pyrimidinderivate und ihre verwendung zur behandlung von krebs und anderen erkrankungen
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EA201500447A1 (ru) * 2009-05-27 2017-03-31 Селекта Байосайенсиз, Инк. НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
EA023897B1 (ru) 2009-08-26 2016-07-29 Селекта Байосайенсиз, Инк. Композиции, которые индуцируют хелперное действие т-клеток
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011068233A1 (en) 2009-12-03 2011-06-09 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP6026405B2 (ja) 2010-04-30 2016-11-16 テロルメディクス エセアー リン脂質薬物類似体
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
CN107029222A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
IT1401281B1 (it) * 2010-08-05 2013-07-18 Univ Firenze Preparazione di coniugati fra derivati dell'adenina e proteine allergeniche e loro uso in immunoterapia specifica per il trattamento delle malattie allergiche.
US20120083473A1 (en) 2010-09-21 2012-04-05 Johanna Holldack Treatment of conditions by toll-like receptor modulators
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
EP2651937B8 (de) 2010-12-16 2016-07-13 Sumitomo Dainippon Pharma Co., Ltd. Imidazo-[4, 5 -c]-chinolin-1-yl-derivat für die therapie
ES2627433T3 (es) 2010-12-17 2017-07-28 Sumitomo Dainippon Pharma Co., Ltd. Derivados de purina
AR085633A1 (es) * 2011-03-08 2013-10-16 Baylor Res Inst Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
BR112013025987B1 (pt) 2011-04-08 2021-04-06 Janssen Sciences Ireland Uc Derivados de pirimidina para o tratamento de infecções virais, composição farmacêutica que os compreende e uso dos mesmos
EA028254B1 (ru) 2011-05-18 2017-10-31 Янссен Сайенсиз Айрлэнд Юси Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EP3366311B1 (de) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazochinolin-4-amine und daraus hergestellte konjugate
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
EA033830B1 (ru) 2011-11-09 2019-11-29 Janssen Sciences Ireland Uc Производные аденина в качестве активаторов толл-подобных рецепторов tlr7
MY169159A (en) 2012-02-08 2019-02-19 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
TWI619704B (zh) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
MY167797A (en) 2012-07-13 2018-09-26 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
AU2013301450B2 (en) 2012-08-10 2018-01-18 Janssen Sciences Ireland Uc Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2712866A1 (de) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-Triazinderivate zur Behandlung von Virusinfektionen
SI2906563T1 (en) 2012-10-10 2018-06-29 Janssen Sciences Ireland Uc Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases
WO2014076221A1 (en) 2012-11-16 2014-05-22 Janssen R&D Ireland Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
HUE051988T2 (hu) 2013-01-07 2021-04-28 Univ Pennsylvania Készítmények és eljárások bõr T-sejt lymphoma kezelésére
EP2958900B1 (de) 2013-02-21 2019-04-10 Janssen Sciences Ireland Unlimited Company 2-aminopyrimidinderivate zur behandlung von virusinfektionen
CA2902560A1 (en) 2013-03-14 2014-09-25 President And Fellows Of Harvard College Nanoparticle-based compositions
MX366481B (es) * 2013-03-29 2019-07-09 Janssen Sciences Ireland Uc Deaza-purinonas macrociclicas para el tratamiento de infecciones virales.
CN105377833B (zh) 2013-05-24 2018-11-06 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的吡啶酮衍生物
SG10201803331PA (en) 2013-06-27 2018-06-28 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
ES2836881T3 (es) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales
US10821175B2 (en) 2014-02-25 2020-11-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3160453A1 (de) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Verfahren und zusammensetzungen zur behandlung mit synthetischen nanoträgern und immun-checkpoint-hemmern
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
CN106661034B (zh) 2014-08-15 2019-11-29 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
US10414768B2 (en) * 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2016164640A1 (en) * 2015-04-09 2016-10-13 Carson Dennis A Synthetic tlr4 and tlr7 ligands to prevent, inhibit or treat liver disease
EP3349717A4 (de) 2015-09-17 2019-04-17 JRX Biotechnology, Inc. Ansätze zur verbesserung der hauthydrierung oder -befeuchtung
US10597397B2 (en) 2015-09-29 2020-03-24 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
TWI558709B (zh) * 2015-10-07 2016-11-21 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine ring compounds, their use and pharmaceutical compositions
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CA3027471A1 (en) 2016-07-01 2018-01-04 Janssen Sciences Ireland Unlimited Company Dihydropyranopyrimidines for the treatment of viral infections
IL293475B2 (en) * 2016-08-29 2024-10-01 Hoffmann La Roche 7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
CN109790154B (zh) 2016-09-29 2023-06-23 爱尔兰詹森科学公司 用于治疗病毒感染和另外的疾病的嘧啶前药
TWI808066B (zh) 2016-12-05 2023-07-11 美商亞博創新醫藥有限公司 含有酸基之嘧啶化合物
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
US11253476B2 (en) 2017-03-29 2022-02-22 Sumitomo Dainippon Pharma Co., Ltd. Vaccine adjuvant formulation
US10494370B2 (en) * 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
WO2019124500A1 (ja) 2017-12-21 2019-06-27 大日本住友製薬株式会社 Ｔｌｒ７アゴニストを含む併用薬
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
TW202415645A (zh) 2018-03-01 2024-04-16 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
AU2019274655B2 (en) 2018-05-23 2023-03-09 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
SI3797121T1 (sl) 2018-05-23 2024-09-30 Pfizer Inc. Protitelesa, specifična za CD3, in njihova uporaba
EP3802519A1 (de) 2018-06-04 2021-04-14 Apros Therapeutics, Inc. Pyrimidinverbindungen mit sauren gruppen zur behandlung von krankheiten im zusammenhang mit der modulation von tlr7
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
WO2020023680A1 (en) * 2018-07-24 2020-01-30 Torque Therapeutics, Inc. Tlr7/8 agonists and liposome compositions
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
US20220241402A1 (en) 2019-06-18 2022-08-04 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
BR112023000701A2 (pt) 2020-07-17 2023-02-07 Pfizer Anticorpos terapêuticos e usos dos mesmos
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78643A0 (en) 1985-05-02 1986-08-31 Wellcome Found Purine derivatives,their preparation and pharmaceutical compositions containing them
GB8511222D0 (en) 1985-05-02 1985-06-12 Wellcome Found Antiviral compounds
JPH08165292A (ja) 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
CA2230808C (en) 1996-07-03 2006-08-15 Japan Energy Corporation A novel purine derivative
AU724042B2 (en) 1996-10-25 2000-09-07 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of TH2 mediated and related diseases

Also Published As

Publication number Publication date
ES2205573T3 (es) 2004-05-01
CA2311742A1 (en) 1999-06-10
TWI222973B (en) 2004-11-01
AU732361B2 (en) 2001-04-26
CA2311742C (en) 2009-06-16
NZ504800A (en) 2001-10-26
US6329381B1 (en) 2001-12-11
DE69817393D1 (de) 2003-09-25
EP1035123A1 (de) 2000-09-13
AU1260299A (en) 1999-06-16
EP1035123A4 (de) 2001-12-12
KR20010032571A (ko) 2001-04-25
WO1999028321A1 (fr) 1999-06-10
EP1035123B1 (de) 2003-08-20
DE69817393T2 (de) 2004-06-17
KR100613634B1 (ko) 2006-08-18
JP4375901B2 (ja) 2009-12-02
WO1999028321A9 (fr) 1999-09-10

Similar Documents

Publication Publication Date Title
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
DK459086A (da) Quinazolinderivater
DE69418704D1 (de) Anthranilsäure derivate
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
ATE145906T1 (de) Benzamid-derivate
DE69001722D1 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
DK0420121T3 (da) Antitumormiddel
DK0420224T3 (da) Anthihepatopatisk middel
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
FI895139A0 (fi) Pyrrolidinderivat.
DE69523819D1 (de) Quinolin-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
TW275629B (de)
DE3884878D1 (de) Uricosuretische Zusammensetzung.
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1035123

Country of ref document: EP